
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences Inc. showcases a promising outlook due to the encouraging initial results from its SENTI-202 product candidate, which compares favorably to existing therapies that have less than a 33% complete response rate. Furthermore, the company's investment in establishing in-house GMP manufacturing capabilities suggests enhanced operational efficiency and potential cost reductions, which could positively affect future financial performance. Overall, there is a belief that if upcoming results in 4Q25 continue to outperform benchmarks in terms of patient response and treatment durability, significant upside potential may be realized for Senti Biosciences.
Bears say
Senti Biosciences faces potential downward revisions in its price target due to concerning risk-adjusted projections related to its development pathways. The repeated emphasis on possible negative adjustments to financial estimates indicates a lack of confidence in the company’s ability to achieve its projected milestones. Therefore, the current financial outlook reflects significant uncertainty surrounding Senti Biosciences' future performance in the competitive biotechnology landscape.
This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares